Last reviewed 2026-04-23 · How we verify

IAC regimen

IAC regimen is a chemotherapy combination that uses ifosfamide, doxorubicin, and cisplatin to damage cancer cell DNA and inhibit tumor growth.

IAC regimen is a chemotherapy combination that uses ifosfamide, doxorubicin, and cisplatin to damage cancer cell DNA and inhibit tumor growth. Used for Soft tissue sarcoma, Osteosarcoma, Other solid tumors (investigational).

At a glance

Mechanism of action

IAC is a multi-agent chemotherapy regimen combining three cytotoxic drugs with complementary mechanisms: ifosfamide (alkylating agent), doxorubicin (topoisomerase II inhibitor and intercalating agent), and cisplatin (platinum-based alkylating agent). Together, these agents create multiple forms of DNA damage to achieve synergistic anti-tumor effects, particularly in sarcomas and other solid tumors.

Approved indications

• Soft tissue sarcoma
• Osteosarcoma
• Other solid tumors (investigational)

Common side effects

• Myelosuppression (neutropenia, thrombocytopenia)
• Nausea and vomiting
• Cardiotoxicity (doxorubicin-related)
• Nephrotoxicity (cisplatin-related)
• Hemorrhagic cystitis (ifosfamide-related)
• Alopecia

Key clinical trials

• Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
• Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML (PHASE2)
• Intermediate-dose HAD Regimen for CEBPA Double-mutated AML (NA)
• Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) (PHASE3)
• Hematopoietic Stem Cell Microtransplantation for in AML (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.